Olr507 inhibitors represent a class of chemical compounds specifically designed to interact with the Olr507 receptor, a member of the olfactory receptor (OR) family. Olfactory receptors are G protein-coupled receptors (GPCRs) that are primarily known for their role in detecting odorant molecules in the olfactory system. However, recent studies have uncovered a broader physiological role for these receptors beyond olfaction. Olr507, in particular, is a receptor that has garnered interest due to its unique ligand-binding properties and its involvement in various signaling pathways. The inhibition of Olr507 receptors involves the binding of specific molecules to the receptor site, preventing the receptor from interacting with its natural ligands. This inhibition can modulate the signaling pathways in which Olr507 is involved, thereby altering the receptor's downstream effects.
Chemically, Olr507 inhibitors can vary widely in structure, depending on their specific mode of action and target affinity. Some inhibitors are small organic molecules that mimic the receptor's natural ligands, thereby blocking the receptor's active site. Others might be larger molecules or even peptides that interact with different parts of the receptor, leading to allosteric inhibition. The design and synthesis of Olr507 inhibitors require a deep understanding of the receptor's structural biology, including the three-dimensional conformation of the receptor and the specific residues involved in ligand binding. Advanced techniques such as X-ray crystallography, molecular docking, and computational modeling are often employed to elucidate these interactions and to design inhibitors with high specificity and potency. The chemical properties of these inhibitors, such as their solubility, stability, and permeability, are critical factors in their effectiveness, and extensive research is often conducted to optimize these properties for various applications in biochemical and physiological research.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, potentially affecting proteins involved in cell growth and proliferation pathways. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $87.00 $147.00 | 5 | |
Aromatase inhibitor, potentially affecting estrogen synthesis and related protein pathways. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Inhibits histone deacetylases, potentially affecting gene expression and proteins involved in chromatin remodeling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual inhibitor of EGFR and HER2, potentially affecting proteins in associated signaling pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits EGFR tyrosine kinase, potentially affecting proteins in the EGFR signaling pathway. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits BCR-ABL tyrosine kinase, potentially affecting proteins in leukemia-associated pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, potentially affecting proteins in cell signaling and growth pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted tyrosine kinase inhibitor, potentially influencing proteins involved in angiogenesis and tumor growth. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, potentially affecting protein degradation and cell cycle regulation. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Inhibits VEGF receptors, potentially affecting proteins involved in angiogenesis and tumor growth. | ||||||